EMBRACA

Background

Phase III, open-label RCT. N=431 with germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer; ≤3 prior cytotoxic regimens. Talazoparib is a potent PARP inhibitor (PARP trapping at DNA damage sites). 2:1 randomization.

Interventions and follow up

Arm A: Talazoparib 1mg oral daily continuously
Arm B: Physician's choice chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine)
Primary endpoint: Progression-free survival (PFS)
mFollow up: 11.2 months

Results

PFS: 8.6 vs 5.6mo, HR 0.54, 95% CI 0.41–0.71, P<.001
OS: 22.3 vs 19.5mo, HR 0.76, 95% CI 0.55–1.06 — NS
ORR: 62.6% vs 27.2%
PROs: Significantly better with talazoparib (global health status, fatigue, nausea/vomiting, pain)

Adverse events

Hematologic (grade ≥3, talazoparib vs chemo): Anemia 39.2% vs 6.3% (transfusion in ~20%); thrombocytopenia 14.9% vs 3.3%; neutropenia 20.8% vs 12.5%
Secondary malignancy: MDS/AML 0.5% vs 0.0%
Other: Alopecia 26.6% vs 28.0% (similar)

Conclusions

Talazoparib significantly improved PFS (HR 0.54) and ORR with better patient-reported QoL vs chemotherapy in gBRCA1/2-mutated HER2-negative mBC. OS was not significantly improved.

Key Limitations

Grade ≥3 anemia in 39% — higher than olaparib (OlympiAD 16%) and chemotherapy (6%); requires monitoring and frequent transfusion. OS non-significant, likely from crossover (~23%) and subsequent therapies. No head-to-head talazoparib vs olaparib comparison.

Clinical Context

FDA approved talazoparib (Talzenna) 2018 for gBRCA1/2-mutated HER2-negative locally advanced/mBC. ESMO-MCBS 3. Together with OlympiAD established PARP inhibitors as preferred oral therapy in gBRCA-mutated mBC. Higher potency may improve efficacy at the cost of more anemia.

References